March 29, 2020Circulation183 citationsOpen Access
Ver artículo completoPeripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
PICO estructurado
Does alirocumab reduce PAD events and VTE in statin-treated patients with recent acute coronary syndrome?
P
Población
statin-treated patients with recent acute coronary syndrome
I
Intervención
alirocumab
O
Resultado
Peripheral Artery Disease (PAD) events and Venous Thromboembolic (VTE) eventshard clinical
Alirocumab reduces the risk of PAD events in statin-treated patients with recent ACS, with the greatest benefit seen in those with high lipoprotein(a) levels.
Resumen
In statin-treated patients with recent acute coronary syndrome, risk of PAD events is related to lipoprotein(a) level and is reduced by alirocumab, particularly among those with high lipoprotein(a). Further study is required to confirm whether risk of VTE is related to lipoprotein(a) level and its reduction with alirocumab. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01663402.